Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes

Novo Nordisk A/S619 enrolled

Overview

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.

Study Type

OBSERVATIONAL

Enrollment

619

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspartDRUG

Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * HbA1c over 7% * No contraindication with NovoMix® 70 Exclusion Criteria: * Type 1 diabetes * Subjects participating in a clinical trial or another observational study * Subjects under previous basis-bolus insulin therapy * Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method

Locations (1)

Unnamed facility

Vienna, Austria

Outcomes

Primary Outcomes

number of major and minor hypoglycaemic events and adverse events

Time frame: 3 months

Secondary Outcomes

HbA1c

Time frame: 3 months

PPBG

Time frame: 3 months

FBG

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.